KR20240131416A - 거대고리 화합물 및 키나제 억제제로서의 용도 - Google Patents

거대고리 화합물 및 키나제 억제제로서의 용도 Download PDF

Info

Publication number
KR20240131416A
KR20240131416A KR1020247025807A KR20247025807A KR20240131416A KR 20240131416 A KR20240131416 A KR 20240131416A KR 1020247025807 A KR1020247025807 A KR 1020247025807A KR 20247025807 A KR20247025807 A KR 20247025807A KR 20240131416 A KR20240131416 A KR 20240131416A
Authority
KR
South Korea
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
methyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247025807A
Other languages
English (en)
Korean (ko)
Inventor
진그롱 장 쿠이
유진 유안진 루이
에반 더블유. 로저스
다용 자이
Original Assignee
블로썸힐 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 블로썸힐 테라퓨틱스, 인크. filed Critical 블로썸힐 테라퓨틱스, 인크.
Publication of KR20240131416A publication Critical patent/KR20240131416A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020247025807A 2022-01-05 2023-01-03 거대고리 화합물 및 키나제 억제제로서의 용도 Pending KR20240131416A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263296705P 2022-01-05 2022-01-05
US63/296,705 2022-01-05
US202263435654P 2022-12-28 2022-12-28
US63/435,654 2022-12-28
PCT/US2023/060039 WO2023133375A1 (en) 2022-01-05 2023-01-03 Macrocyclic compounds and use as kinase inhibitors

Publications (1)

Publication Number Publication Date
KR20240131416A true KR20240131416A (ko) 2024-08-30

Family

ID=87074235

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247025807A Pending KR20240131416A (ko) 2022-01-05 2023-01-03 거대고리 화합물 및 키나제 억제제로서의 용도

Country Status (10)

Country Link
US (1) US20250074920A1 (https=)
EP (1) EP4460498A4 (https=)
JP (1) JP2025503592A (https=)
KR (1) KR20240131416A (https=)
AU (1) AU2023204770A1 (https=)
CA (1) CA3246487A1 (https=)
IL (1) IL314070A (https=)
MX (1) MX2024008413A (https=)
TW (1) TW202334168A (https=)
WO (1) WO2023133375A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024266587A1 (en) * 2023-05-02 2025-09-11 Blossomhill Therapeutics, Inc. Egfr inhibitors for treating disease
WO2025212729A1 (en) * 2024-04-03 2025-10-09 Blossomhill Therapeutics, Inc. Macrocyclic compounds and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03376B (me) * 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
US20160031888A1 (en) * 2013-03-13 2016-02-04 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
ES2933350T3 (es) * 2014-01-24 2023-02-06 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteína quinasas
TWI707852B (zh) * 2015-09-02 2020-10-21 美商林伯士拉克許米公司 Tyk2 抑制劑及其用途
EP4178958A4 (en) * 2020-07-10 2024-12-11 Blossomhill Therapeutics, Inc. MACROCYCLES AND THEIR USE

Also Published As

Publication number Publication date
CA3246487A1 (en) 2023-07-13
MX2024008413A (es) 2024-09-17
US20250074920A1 (en) 2025-03-06
TW202334168A (zh) 2023-09-01
EP4460498A1 (en) 2024-11-13
EP4460498A4 (en) 2026-03-25
JP2025503592A (ja) 2025-02-04
AU2023204770A1 (en) 2024-07-18
WO2023133375A1 (en) 2023-07-13
IL314070A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
JP7644517B2 (ja) Ｋｒａｓ突然変異型タンパク質阻害剤
KR102599788B1 (ko) 단백질 키나제의 조절물질로서 키랄 디아릴 매크로사이클
WO2023280136A1 (zh) 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
EP3636648A1 (en) Diaryl macrocycles as modulators of protein kinases
WO2018045956A1 (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
WO2019134539A1 (zh) 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
CN103582638B (zh) 杂芳基并嘧啶类衍生物、其制备方法和用途
AU2017302019A1 (en) Macrocycle kinase inhibitors
KR20230121773A (ko) 거대고리 화합물 및 그의 용도
BR112015002709B1 (pt) Compostos, composição farmacêutica, uso dos mesmos e uso de uma combinação de composto ou composição farmacêutica e um segundo agente profilático ou agente terapêutico
JP2023520595A (ja) ピラゾロピリダジノン化合物、その医薬組成物及びその用途
KR20240131416A (ko) 거대고리 화합물 및 키나제 억제제로서의 용도
WO2015058661A1 (zh) Bcr-abl激酶抑制剂及其应用
WO2023240140A1 (en) Indazole macrocycles and their use
US20240383911A1 (en) Azaindazole macrocycle compounds and uses thereof
TW202345806A (zh) 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
WO2024012425A1 (zh) 作为ripk1抑制剂的杂环化合物
JP2025507308A (ja) 化学療法剤および組織結合小分子のコンジュゲート、組成物、ならびにその方法
TWI652265B (zh) 氮雜吲哚衍生物
CN118946559A (zh) 大环化合物及其作为激酶抑制剂的用途
KR20260030889A (ko) 거대고리 화합물 및 tyk2 억제제로서의 용도
HK40119440A (zh) 大环化合物及其作为激酶抑制剂的用途
WO2025199438A1 (en) 7-azaindazole macrocycles and their use
WO2026064346A1 (en) Tetracyclic-macrocycles and their use
WO2025212729A1 (en) Macrocyclic compounds and their use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000